World

US health regulator authorizes pfizers covid pill for corona vaccine. Paxlovid tablet approved for the treatment of corona, also effective in fighting Omicron

Spread the love


Image Source : INDIA TV
Paxlovid tablet approved for the treatment of corona

Highlights

  • The US Food and Drug Administration has given Pfizer’s Paxlovid tablet
  • It is 89 percent effective in reducing the risk of hospitalization of patients or death in critical patients
  • This tablet is made by American company Pfizer. It is named Paxlovid.

Washington: The new infection of the corona virus, Omicron, has created an outcry all over the world. Everyone is scared of this, but in the meantime a relief news is coming. The US Food and Drug Administration on Wednesday approved Pfizer’s Paxlovid tablet in the fight against the coronavirus. Now Paxlovid tablet can be used in the treatment of Kovid epidemic of people at high risk of 12 years and above.

It is 89 percent effective in reducing the risk of hospitalization of patients or death in critical patients.

FDA scientist Patrizia Cavazzoni said, “A tablet has been successfully made for the treatment of corona virus, which has become an epidemic in many countries of the world. This is a historic step in the global fight against corona.”

This tablet is made by American company Pfizer. It has been named Paxlovid.

Trial done on 2246 patients-

These results from the Pfizer company confirm its interim results conducted on 1,200 people last month, and the final results include trials conducted on 2246 patients who were included in the research on November 4. The company has also said that PaxLovid is also effective against the more modified Omicron of Corona.

Medicine will prove to be very effective in saving lives-
Albert Borula, CEO and President of Pfizer, said that our results prove that if this drug is allowed to be used, it will prove to be very effective in saving lives. This drug reduces the risk of hospitalization and death of corona patients. It has also been found to be effective against Omicron.

70 percent lower risk of hospitalization
The company has also released preliminary results of a second clinical trial that found a 70 percent reduction in the risk of hospitalization in 600 moderate-risk patients. The company expects to get approval from the Food and Drug Administration soon.

Total five days course-
The complete course of this medicine is of five days in which three tablets have to be taken twice and two tablets are anti-virus Nirmatrelvir and the third tablet is Ritonavir currently given in HIV infection.

.

Abdullah Shafqat

Abdullah Shafqat is a journalist at UsamaSpeaks.com and he deals with World News, Education News, and Authorized Images gallery. Abdullah Shafqat is a very professional and authentic news journalist.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
%d bloggers like this: